Paraneoplastic neurologic syndromes are degenerative diseases of the central or peripheral nervous system that develop in association with a systemic neoplasm without a direct invasion by tumor. The pathogenesis of this disorder has been hypothesized in the past, and now there is increasing evidence that autoimmune processes triggered by the underlying neoplasm play a major role in the pathophysiology, as documented by many reports of identification ofautoantibodies that react with both the target neural tissue and the underlying neoplasm, as evidenced by the extensive application of molecular biology techniques. The presence of antibodies in serum or CSF of some patients with this disorder nowaccurately identifies the subgroup of the disorders related to specific neoplasms. The trend of recent studies on the pathogenesis of this disease may in the future lead to a new era to clarify the pathogenesis. (Internal Medicine 35: 925-929, 1996) 
Introduction
Anassociation betweenmalignant disease such as carcinomaand specific neuro-muscular diseases independent of metastasis has been well recognized by a number of papers (1, 2). The term paraneoplastic syndrome was first introduced by Shnider et al (3) in 1979 for a group of disorders that are associated with cancer without a direct invasion by the primary tumor massor metastasis to the involved organ. Therefore paraneoplastic syndromes can affect manyorgans. Among paraneoplastic syndromes, paraneoplastic neurologic syndromes include the disorders of all nervous systems in patients with systemic cancer not caused by tumor mass, metastasis or radiation effect (Table 1 ) . These disorders once were named as remote effects of cancer on the nervous system (4), but there is increasing evidence that autoimmunemechanisms caused by the underlying malignancy play a majorrole in the pathogenesis. This autoimmune theory has been supported by the identification of antibodies that react with both the target neurologic organ and the underlying cancer (onconeural antigen) in the serum of patients with this disorder. The presence of serum antibodies in some paraneoplastic neurologic syndromes now identifies subgroups of patients with particular paraneoplastic syndromesrelated to specific cancers. Nowwe have more information regarding the pathogenesis of this disorder via the extensive use of molecular biology techniques. However, the true pathogenesis is yet to be defined.
Incidence
The The background of autoimmune pathogenesis is based on the hypothesis that quiescent memory T-cells, exposed to the antigen in fetal life might escape from thymic deletion and stay in the periphery until the antigen is abnormally expressed by the presence of a tumor and processed by antigen presenting cells. T-cell mediated B-cell proliferation in response to tumor antigen would result in production of autoantibody, which would erroneously be targeted at a similar neuronal antigenic epitope. Finally complement-mediated antibody-dependent cytotoxicity or antigen-dependent T-cell and cytokine-mediated neuronal damage or lysis would occur (9) .
Several autoantibodies and their associated antigens have now been characterized by the molecular biology techniques in paraneoplastic neurologic syndromes ( Table 2 ). The presence of these antibodies in some patients with paraneoplastic neurologic syndromecan be used as a diagnostic marker that the patient with a neurologic disorder has underlying cancer.
In regard to the antibody-negative patients, there are two possibilities that the disorder is not autoimmuneor is autoimmune, and antibody is present in serum, but this has not been identified by our current methodologies.
Specific Clinical Syndromes
Encepha lomyelitis-sensory neuronopathy The term "encephalomyelitis associated with carcinoma" was introduced by Henson et al (19) fasciculation is often seen in association with corticospinl and posterior column signs. In patients with sensory neuronopathy, the onset is subacute, often accompanied by dysesthetic pain in distal limbs. The symptomsspread to proximal limbs and the trunk. Finally sensory ataxia ensues. Nerve conduction studies reveal delayed sensory nerve latencies with preservation of motor nerve conduction.
Most of the patients with this type encephalomyelitis have mild mononuclear cell pleocytosis, elevated IgG content and oligoclonal IgG bands in CSF. Commonpathological findings in these disorders include neuronal loss, gliosis, mononuclear cell infiltration, microglia proliferation, and secondary tract degeneration.
Anti-neuronal nuclear antibody (21), type 1, also called "anti-Hu" (22) was present in serum and CSF of patients with this disease. This antibody is synthesized in the CNSas well as systemically and is localized in the tumor and in areas of the lesions of the nervous system. This antibody binds to a 35-40kD neuronal protein antigen. The targets of this antibody defined by molecular biological techniques belong to a family of RNA-binding proteins, that includes HuD (10), HuC (1 1)/ ple21 (12) and Hel-Nl (13). Werecently identified a new hippocampal autoantigen which was recognized by the antibody present in the serum of a patient with paraneoplastic limbic encephalitis and small cell lung cancer (12) . The isolated CDNAcloneplell comprises an ORF of 1,053 nucleotides encoding a 350 aminoacid protein with deduced molecular weight of 38kD (Fig. 1) . The antigen was not only recognized by the antibody from a patient with paraneoplastic limbic encephalitis, but also was recognized by the sera from the patients with SCLC-associated paraneoplastic sensory neuronopathy (Fig. 2) . This autoantigen is highly
homologousto HuCantigen in its aminoacid sequence.
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